It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Backgrounds
Limited information is available on the utility values of metastatic pancreatic cancer, focusing on different health statuses, selected chemotherapy, and related grades 1/2 and 3/4 adverse events (AEs). We evaluated Japanese societal-based health-related utility values for metastatic pancreatic cancer by considering different grade toxicities commonly associated with chemotherapy using the vignette-based method.
Methods
We developed health status scenarios for patients with metastatic pancreatic cancer undergoing chemotherapy and conducted utility research using the developed scenarios in four steps: ‘literature review,’ ‘exploratory interview,’ ‘content validation’, and ‘utility research’. In the development process, to consider the impact of AEs of chemotherapy for metastatic pancreatic cancer on health state utility values, we selected neutropenia, febrile neutropenia, diarrhea, nausea and vomiting, and neuropathy as representative AEs. Each AE was classified as either grade 1/2 or 3/4. We confirmed our created scenarios through cognitive interviews with the general population and clinical experts to validate the content. Finally, we developed 11 scenarios for using ‘utility research,’ evaluated in a societal-based valuation study using the face-to-face method. Participants for ‘utility research’ were the general population, and they evaluated these scenarios in the composite time trade-off (cTTO) and visual analog scale (VAS) of the European quality of life (EuroQol) valuation technology to derive health state utility scores.
Results
Of 220 responders who completed this survey, 201 were adapted into the analysis population. Stable disease with no AEs (reference state) had a mean utility value of 0.653 using cTTO. The lowest mean utility score in the stable state was 0.242 (stable disease + grade 3/4 vomiting). VAS results ranged from 0.189 to 0.468, depending on the various grades of AEs in stable disease. In addition, grade 3/4 AEs and grade 1/2 nausea/vomiting were associated with significantly greater disutility. Utility values were also strongly influenced by the direct impact of AE on physical symptoms, severity and their experience. In addition, 95.9% of the respondents agreed that they understood the questions in the post-response questionnaire.
Conclusions
We clarified the health state utility values of patients with metastatic pancreatic cancer based on the general population in Japan. The effect on utilities should be considered not only for serious AEs, but also for minor AEs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Meiji Pharmaceutical University, Department of Public Health and Epidemiology, Tokyo, Japan (GRID:grid.411763.6) (ISNI:0000 0001 0508 5056); National Institute of Public Health, Center for Outcomes Research and Economic Evaluation for Health, Saitama, Japan (GRID:grid.415776.6) (ISNI:0000 0001 2037 6433)
2 Yamagata Prefectural Central Hospital, Department of Medical Oncology, Yamagata, Japan (GRID:grid.417323.0) (ISNI:0000 0004 1773 9434)
3 Kanagawa Cancer Center, Department of Genetic Medicine, Yokohama, Japan (GRID:grid.414944.8) (ISNI:0000 0004 0629 2905); Kanagawa Cancer Center Research Institute, Cancer Prevention and Cancer Control Division, Yokohama, Japan (GRID:grid.414944.8) (ISNI:0000 0004 0629 2905); Kanagawa University of Human Services, Graduate School of Health Innovation, Yokohama, Japan (GRID:grid.444024.2) (ISNI:0000 0004 0595 3097)
4 CRECON Medical Assessment Inc, Tokyo, Japan (GRID:grid.444024.2)
5 Meiji Pharmaceutical University, Department of Public Health and Epidemiology, Tokyo, Japan (GRID:grid.411763.6) (ISNI:0000 0001 0508 5056)